Navigation Links
Ameritox Files Amended Complaint Against Millennium Laboratories For Injunctive Relief, Declaratory Relief and Damages

BALTIMORE, April 20, 2012 /PRNewswire/ -- Ameritox, the national leader in pain medication monitoring, today announced that it filed an amended complaint against San Diego-based Millennium Laboratories seeking damages, injunctive and other relief for false advertising, unfair competition, and unfair trade practices.  The Ameritox filing alleges that numerous Millennium Laboratories' business practices have resulted in violations of the Lanham Act, unfair competition in accordance with the Florida Deceptive and Unfair Trade Practices Act, California Business and Professions Code, New Hampshire Consumer Protection Act and national laws relating to unfair competition.

"It is tremendously harmful to physicians, their patients and the industry when a laboratory's business model, as alleged in this case against Millennium Laboratories, effectively flies in the face of ethical and legal business conduct and the healthcare provider's decision-making process," said Dr. Harry Leider, Chief Medical Officer at Ameritox. "These practices of providing financial incentives that mislead health professionals into believing that it is lawful for them to accept illegal inducements are a disservice to the public and the industry.  All companies must be held to the same high standards in providing patient-care services."

Federal Anti-Kickback Statute and numerous state anti-kickback statutes, including those of Arizona, Florida, California, New Hampshire and Texas, prohibit companies from providing financial inducements to health providers in order to induce the referral of business. These laws prohibit direct payments to physicians as an inducement for the referral of business, and prohibit other forms of kickbacks, such as the provision of equipment, supplies, tests, services, and other benefits to the health care provider at no cost or at below fair market value, as alleged against Millennium Laboratories. 

Ameritox, as the national leader in pain medication monitoring, believes it is important to provide a transparent exchange of business practices. The Company's programs are subject to OIG verification and Ameritox adheres to the highest standards in Federal and state policy.

Reporters have online access to complete documentation for this case -- Ameritox, LTD. V. Millennium Laboratories, Inc. in the UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA TAMPA DIVISION – via the public access service Public Access to Court Electronic Records (PACER).  Case number is 8:11-cv-00775-SCB-TBM.

About Ameritox

Ameritox is the nation's leader in pain medication monitoring solutions, offering specialized laboratory testing and reporting services. Ameritox's expertise and innovative science provide physicians with insights and support to enhance and optimize the care of chronic pain patients. Ameritox offers the most thorough pain medication monitoring lab process — Rx Guardian(SM) — with Rx Guardian CD(SM), the only pain medication monitoring solution with a proprietary normalization algorithm and a reference database of pain patients assessed for medication adherence. Patient results are compared against this database, helping physicians assess whether patients are taking their pain medications correctly. Medication monitoring through urine drug testing helps physicians make more informed clinical decisions and manage the risks and complexities associated with prescribing pain medications. Ameritox is headquartered in Baltimore, Md. with laboratory facilities in Midland, Texas and Greensboro, N.C. Ameritox can be found online at, on Twitter @Ameritox, on LinkedIn at or on Facebook at


For more information, contact:

Lon Wagner
Office: 336-387-7742


SOURCE Ameritox
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ameritox(R) Appoints Jay B. Zimmerman as Chief Operating Officer
2. Ameritox® Continues to Advance Industry Leadership
3. Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients
4. Ameritox Provides Educational Support to Clinicians to Help Reduce Opioid Misuse, Abuse and Diversion
5. Ameritox Supports New Expert Consensus Recommendations For Patients on Long-Term Opioid Therapy
6. Ameritox Commends Operation UNITE on Its Inaugural National Rx Drug Abuse Summit
7. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
8. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
9. AngioGenex Files Patent on First Small Molecule Id-Inhibitors for the Treatment of Cancer
10. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
11. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... -- 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ... transplantation is expected to boost the market growth, as 3D ... --> 3D bioprinting market is expected to ... report by Grand View Research Inc. Rising prevalence of chronic ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 /PRNewswire/ ... the addition of the "2016 Future ... Drugs of Abuse Testing Market: Supplier Shares, ... report to their offering. --> ... of the "2016 Future Horizons and ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... training center for the Narconon network, announced the release of a new cutting edge ... the Narconon organization has been working with drug- and alcohol-addicted individuals with the purpose ...
(Date:11/25/2015)... , ... November 25, 2015 , ... On November 23rd ... Tri Lite’s personal heating products business. Cozy Products explains what this means ... that fit in well with the Cozy Products business model: to sell personal heaters ...
(Date:11/25/2015)... ALTO, Calif. (PRWEB) , ... November 25, 2015 , ... ... Smart and Beddit Classic sleep tracking systems. The new app features a more intuitive ... see and understand how well you slept. The SleepScore is created by a proprietary ...
(Date:11/25/2015)... ... November 25, 2015 , ... “While riding the bus, I saw a ... “I thought there had to be a convenient and comfortable way to protect them ... enables disabled individuals to safely travel during cold or inclement weather. In doing so, ...
(Date:11/25/2015)... , ... November 25, 2015 , ... ... (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care ... disease. The Periwinkle Pioneers, nominated by the public, will receive special recognition throughout ...
Breaking Medicine News(10 mins):